We know 1 in 8 women will develop breast cancer in their lifetime, but, to date, it has been very difficult to identify who is at risk. Current risk models are good at identifying populations at risk, but that does not help the specific patient understand her risk. Further, 8 out of 9 women that develop breast cancer will not have a direct relative with the disease. In other words, most women who develop cancer are not traditionally defined as "high risk" for the disease.

It is estimated that half of all women in the U.S. will seek consultation for a breast disorder in their lifetime. Many of these women are diagnosed with benign breast disease, defined as any non-cancerous breast abnormality. The most common benign breast tumor is fibroadenoma. Fibroadenomas can grow up to 4 cm or larger, the size of a golf ball, and cause pain, anxiety and disfigurement.

A benign breast condition is any non-cancerous breast abnormality. The most common benign breast conditions include fibrocystic change, benign breast tumors, and breast inflammation. Most benign breast conditions such as fibrocystic change or fibroadenomas (small tumors) do not increase a woman’s risk for breast cancer later in life.

These are the recommendations for screening breast MRI, according to the new American Cancer Society guidelines: first-degree relative (parent, sibling, child) with a BRCA1 or BRCA2 mutation, even if the patient has yet to be tested herself lifetime risk of breast cancer scored at 20%-25% or greater, based on one of several accepted risk assessment tools that look at family history and other factors Li-Fraumeni syndrome, Cowden syndrome, or Bannayan-Riley-Ruvalcaba syndrome, or one of these synd.

Family history and genetics are only two of the risk factors associated with breast cancer. Women who carry mutations of certain genes (such as BRCA1, BRCA2, or p53) are at a higher risk of developing breast cancer than women with no known risk factors. As stated earlier, 80% of women who develop breast cancer have no known risk factors.

Mammograms are the most efficient way of detecting breast cancer early. Like other screening tests, they are not perfect. For example: the person reading the x-ray may miss the cancer. This will happen occasionally, no matter how experienced the reader is. We aim to have two specialists check all the mammograms.

There are many exciting technologies being investigated in the field of breast imaging. All of this work is in the hopes of detecting breast cancer at the earliest stage possible to allow patients the best chance for a cure. One new technology being developed is Tomosynthesis, an adjunct to digital mammography. In conventional mammography, a 3-D structure (the breast) is evaluated with a 2-D image. A major drawback of mammography is that structures can be superimposed on a single image.

It can make you sick, cause fungal abscesses or lesions, debilitate you, cripple you for life, or kill you. It can be unbearably painful and is definitely not a benign disease. Since Valley Fever is initially asymptomatic in under 50% of the people it infects, since the disease causes such a wide variety of symptoms, and since it is misdiagnosed so frequently and can activate or reactivate decades after the initial infection, the actual toll of Valley Fever is difficult to measure.

No. Although men do develop breast cancer (approximately 300 deaths per year in the USA), the vast majority of breast cancers occur in women (about 46,000 deaths per year). Men with abnormal breast symptoms are encouraged to see a health care professional for evaluation.

Mammography screening remains the best available method to detect breast cancer early. In 1992, the U.S. Congress passed the Mammography Quality Standards Act to ensure that mammography facilities throughout the country are of high quality and reliable. To lawfully perform mammography, each facility must prominently display a certificate issued by the U.S. Food and Drug Administration (FDA). This certificate serves as evidence that the facility meets quality standards.

Other screening tests, such as magnetic resonance imaging (MRI) are available, but mammography screening remains the best available method to detect breast cancer early. However, no medical test is always 100 percent accurate, and mammography is no exception. Research is under way to improve the technology to lead to better accuracy and to create new technologies.

Click here to download the Michigan Cancer Consortium recommendations for early detection of breast cancer. (available as an Adobe Acrobat PDF file)*

Download the Q&A document on this topic from our sister site, Women's Health: MS Word (.DOC), 68k | Acrobat Reader (.PDF) 84K

Breast implants may hide up to 25% of breast tissue from x-rays during a mammogram. A study funded by the National Cancer Institute found that mammograms missed 55% of breast cancers in women with breast implants as compared to 33% in women without implants. The technician performing the mammogram should know about the presence of breast implants so that they can use a special technique called "implant displacement views" and take care to avoid causing an implant to rupture.

The two most common types of benign breast lumps are cysts and fibroadenomas. In addition, there are several other conditions that can present themselves as lumps, such as fat necrosis and sclerosing adenosis.

Although there has been no correlation with the herbal ingredients and breast cancer, any woman with known breast conditions should consult with their physician prior to taking any supplements.. back to the top of the page

Women with a fibrocystic disease should continue to do breast self-examination. By getting to know the texture of your own breast, whether they are lumpy, or nodular, and the location of the areas of tenderness, are all important points. When you do breast self-examination, you are feeling for a change. The analogy that another a physician has used for this is like looking for a rock or a boulder in a gravel road.

Breast disease and connective tissue disease (CTD) were reported in some patients through 5 years after implantation in the A95 Study. Although there were 901 patients enrolled in the A95 Study, not every patient returned for each follow-up visit. Therefore, the percentage of patients with these events cannot be determined. Only the number of events can be reported. Without a comparison group of women with similar characteristics (such as age, race, etc.